Phase I and pharmacokinetic study of edotecarin, a novel topoisomerase I inhibitor, administered once every 3 weeks in patients with solid tumors

Yasuhide Yamada, Tomohide Tamura, Noboru Yamamoto, Tatsu Shimoyama, Yutaka Ueda, Haruyasu Murakami, Hitoshi Kusaba, Yoshikazu Kamiya, Hideo Saka, Yusuke Tanigawara, J. Patrick McGovren, Yutaka Natsumeda

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Purpose: Edotecarin (J-107088) is a potent indolocarbazole topoisomerase I inhibitor which is structurally distinct from the camptothecins. This study aimed to determine the maximum tolerated dose (MTD), the recommended dose for future Phase II studies and the safety, pharmacokinetic profile, and preliminary antitumor activity of edotecarin in a population of patients with advanced solid tumors. Experimental design: Edotecarin was administered as a single dose by IV infusion over 2 h every 21 days (with 1 week permitted for recovery from toxicities, if needed) in patients with advanced solid tumors. Doses ranged from 8 to 15 mg/m2. Pharmacokinetic assessments were performed during and after the first administration. Results: Twenty-four patients received 61 cycles of therapy. Dose-limiting toxicities (infection, febrile neutropenia, constipation, ileus, and prolonged grade 4 granulocytopenia) were observed in 3 of 5 evaluable patients at the 15 mg/m2 dose, defining the MTD. The most commonly reported non-hematologic toxicities were anorexia, nausea, malaise, and constipation. Diarrhea was neither frequent nor severe. Neutropenia was the most common hematologic toxicity (grade 3-4 in 21/23 patients during cycle 1). Plasma concentrations of edotecarin rose rapidly following the start of the 2-hour infusion, reaching Cmax values of 103 ± 17 ng/ml at the 13 mg/m2 dose, and decreased steeply after the end of the infusion. Plasma concentrations declined to approximately 1-2 ng/ml at 26 h post start of infusion, the last PK sampling time point. The mean apparent plasma half-life of the drug was 20 h, which should be considered a preliminary estimate until results from studies with a longer duration of plasma sampling are available. A mean of 1.4-3.6% of the dose was recovered as unchanged drug in the urine over 48 h. Unconfirmed tumor regression ≥50% was observed in 2 patients, 1 with metastatic gastric carcinoma and 1 with esophageal cancer. Conclusions: The MTD of edotecarin administered IV over 2 h every 21 days was 15 mg/m2. The recommended dose for Phase II studies with a 3-week schedule (with 1 week permitted for recovery from toxicities, if needed) is 13 mg/m2. The observed safety profile and preliminary evidence of antitumor activity warrant further investigation of this drug in solid tumors.

Original languageEnglish
Pages (from-to)173-182
Number of pages10
JournalCancer Chemotherapy and Pharmacology
Volume58
Issue number2
DOIs
Publication statusPublished - 2006 Aug

Fingerprint

Topoisomerase I Inhibitors
Pharmacokinetics
Tumors
Toxicity
Maximum Tolerated Dose
Plasmas
Neoplasms
Constipation
Pharmaceutical Preparations
Sampling
Safety
Recovery
Febrile Neutropenia
Camptothecin
Agranulocytosis
Ileus
Anorexia
Esophageal Neoplasms
Neutropenia
Design of experiments

Keywords

  • Dose-limiting toxicity
  • Edotecarin
  • Maximum tolerated dose
  • Pharmacokinetics
  • Topoisomerase I inhibitor

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology
  • Oncology

Cite this

Phase I and pharmacokinetic study of edotecarin, a novel topoisomerase I inhibitor, administered once every 3 weeks in patients with solid tumors. / Yamada, Yasuhide; Tamura, Tomohide; Yamamoto, Noboru; Shimoyama, Tatsu; Ueda, Yutaka; Murakami, Haruyasu; Kusaba, Hitoshi; Kamiya, Yoshikazu; Saka, Hideo; Tanigawara, Yusuke; McGovren, J. Patrick; Natsumeda, Yutaka.

In: Cancer Chemotherapy and Pharmacology, Vol. 58, No. 2, 08.2006, p. 173-182.

Research output: Contribution to journalArticle

Yamada, Y, Tamura, T, Yamamoto, N, Shimoyama, T, Ueda, Y, Murakami, H, Kusaba, H, Kamiya, Y, Saka, H, Tanigawara, Y, McGovren, JP & Natsumeda, Y 2006, 'Phase I and pharmacokinetic study of edotecarin, a novel topoisomerase I inhibitor, administered once every 3 weeks in patients with solid tumors', Cancer Chemotherapy and Pharmacology, vol. 58, no. 2, pp. 173-182. https://doi.org/10.1007/s00280-005-0149-6
Yamada, Yasuhide ; Tamura, Tomohide ; Yamamoto, Noboru ; Shimoyama, Tatsu ; Ueda, Yutaka ; Murakami, Haruyasu ; Kusaba, Hitoshi ; Kamiya, Yoshikazu ; Saka, Hideo ; Tanigawara, Yusuke ; McGovren, J. Patrick ; Natsumeda, Yutaka. / Phase I and pharmacokinetic study of edotecarin, a novel topoisomerase I inhibitor, administered once every 3 weeks in patients with solid tumors. In: Cancer Chemotherapy and Pharmacology. 2006 ; Vol. 58, No. 2. pp. 173-182.
@article{ffdd9b28a77441159c3f536d1fe30b1c,
title = "Phase I and pharmacokinetic study of edotecarin, a novel topoisomerase I inhibitor, administered once every 3 weeks in patients with solid tumors",
abstract = "Purpose: Edotecarin (J-107088) is a potent indolocarbazole topoisomerase I inhibitor which is structurally distinct from the camptothecins. This study aimed to determine the maximum tolerated dose (MTD), the recommended dose for future Phase II studies and the safety, pharmacokinetic profile, and preliminary antitumor activity of edotecarin in a population of patients with advanced solid tumors. Experimental design: Edotecarin was administered as a single dose by IV infusion over 2 h every 21 days (with 1 week permitted for recovery from toxicities, if needed) in patients with advanced solid tumors. Doses ranged from 8 to 15 mg/m2. Pharmacokinetic assessments were performed during and after the first administration. Results: Twenty-four patients received 61 cycles of therapy. Dose-limiting toxicities (infection, febrile neutropenia, constipation, ileus, and prolonged grade 4 granulocytopenia) were observed in 3 of 5 evaluable patients at the 15 mg/m2 dose, defining the MTD. The most commonly reported non-hematologic toxicities were anorexia, nausea, malaise, and constipation. Diarrhea was neither frequent nor severe. Neutropenia was the most common hematologic toxicity (grade 3-4 in 21/23 patients during cycle 1). Plasma concentrations of edotecarin rose rapidly following the start of the 2-hour infusion, reaching Cmax values of 103 ± 17 ng/ml at the 13 mg/m2 dose, and decreased steeply after the end of the infusion. Plasma concentrations declined to approximately 1-2 ng/ml at 26 h post start of infusion, the last PK sampling time point. The mean apparent plasma half-life of the drug was 20 h, which should be considered a preliminary estimate until results from studies with a longer duration of plasma sampling are available. A mean of 1.4-3.6{\%} of the dose was recovered as unchanged drug in the urine over 48 h. Unconfirmed tumor regression ≥50{\%} was observed in 2 patients, 1 with metastatic gastric carcinoma and 1 with esophageal cancer. Conclusions: The MTD of edotecarin administered IV over 2 h every 21 days was 15 mg/m2. The recommended dose for Phase II studies with a 3-week schedule (with 1 week permitted for recovery from toxicities, if needed) is 13 mg/m2. The observed safety profile and preliminary evidence of antitumor activity warrant further investigation of this drug in solid tumors.",
keywords = "Dose-limiting toxicity, Edotecarin, Maximum tolerated dose, Pharmacokinetics, Topoisomerase I inhibitor",
author = "Yasuhide Yamada and Tomohide Tamura and Noboru Yamamoto and Tatsu Shimoyama and Yutaka Ueda and Haruyasu Murakami and Hitoshi Kusaba and Yoshikazu Kamiya and Hideo Saka and Yusuke Tanigawara and McGovren, {J. Patrick} and Yutaka Natsumeda",
year = "2006",
month = "8",
doi = "10.1007/s00280-005-0149-6",
language = "English",
volume = "58",
pages = "173--182",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - Phase I and pharmacokinetic study of edotecarin, a novel topoisomerase I inhibitor, administered once every 3 weeks in patients with solid tumors

AU - Yamada, Yasuhide

AU - Tamura, Tomohide

AU - Yamamoto, Noboru

AU - Shimoyama, Tatsu

AU - Ueda, Yutaka

AU - Murakami, Haruyasu

AU - Kusaba, Hitoshi

AU - Kamiya, Yoshikazu

AU - Saka, Hideo

AU - Tanigawara, Yusuke

AU - McGovren, J. Patrick

AU - Natsumeda, Yutaka

PY - 2006/8

Y1 - 2006/8

N2 - Purpose: Edotecarin (J-107088) is a potent indolocarbazole topoisomerase I inhibitor which is structurally distinct from the camptothecins. This study aimed to determine the maximum tolerated dose (MTD), the recommended dose for future Phase II studies and the safety, pharmacokinetic profile, and preliminary antitumor activity of edotecarin in a population of patients with advanced solid tumors. Experimental design: Edotecarin was administered as a single dose by IV infusion over 2 h every 21 days (with 1 week permitted for recovery from toxicities, if needed) in patients with advanced solid tumors. Doses ranged from 8 to 15 mg/m2. Pharmacokinetic assessments were performed during and after the first administration. Results: Twenty-four patients received 61 cycles of therapy. Dose-limiting toxicities (infection, febrile neutropenia, constipation, ileus, and prolonged grade 4 granulocytopenia) were observed in 3 of 5 evaluable patients at the 15 mg/m2 dose, defining the MTD. The most commonly reported non-hematologic toxicities were anorexia, nausea, malaise, and constipation. Diarrhea was neither frequent nor severe. Neutropenia was the most common hematologic toxicity (grade 3-4 in 21/23 patients during cycle 1). Plasma concentrations of edotecarin rose rapidly following the start of the 2-hour infusion, reaching Cmax values of 103 ± 17 ng/ml at the 13 mg/m2 dose, and decreased steeply after the end of the infusion. Plasma concentrations declined to approximately 1-2 ng/ml at 26 h post start of infusion, the last PK sampling time point. The mean apparent plasma half-life of the drug was 20 h, which should be considered a preliminary estimate until results from studies with a longer duration of plasma sampling are available. A mean of 1.4-3.6% of the dose was recovered as unchanged drug in the urine over 48 h. Unconfirmed tumor regression ≥50% was observed in 2 patients, 1 with metastatic gastric carcinoma and 1 with esophageal cancer. Conclusions: The MTD of edotecarin administered IV over 2 h every 21 days was 15 mg/m2. The recommended dose for Phase II studies with a 3-week schedule (with 1 week permitted for recovery from toxicities, if needed) is 13 mg/m2. The observed safety profile and preliminary evidence of antitumor activity warrant further investigation of this drug in solid tumors.

AB - Purpose: Edotecarin (J-107088) is a potent indolocarbazole topoisomerase I inhibitor which is structurally distinct from the camptothecins. This study aimed to determine the maximum tolerated dose (MTD), the recommended dose for future Phase II studies and the safety, pharmacokinetic profile, and preliminary antitumor activity of edotecarin in a population of patients with advanced solid tumors. Experimental design: Edotecarin was administered as a single dose by IV infusion over 2 h every 21 days (with 1 week permitted for recovery from toxicities, if needed) in patients with advanced solid tumors. Doses ranged from 8 to 15 mg/m2. Pharmacokinetic assessments were performed during and after the first administration. Results: Twenty-four patients received 61 cycles of therapy. Dose-limiting toxicities (infection, febrile neutropenia, constipation, ileus, and prolonged grade 4 granulocytopenia) were observed in 3 of 5 evaluable patients at the 15 mg/m2 dose, defining the MTD. The most commonly reported non-hematologic toxicities were anorexia, nausea, malaise, and constipation. Diarrhea was neither frequent nor severe. Neutropenia was the most common hematologic toxicity (grade 3-4 in 21/23 patients during cycle 1). Plasma concentrations of edotecarin rose rapidly following the start of the 2-hour infusion, reaching Cmax values of 103 ± 17 ng/ml at the 13 mg/m2 dose, and decreased steeply after the end of the infusion. Plasma concentrations declined to approximately 1-2 ng/ml at 26 h post start of infusion, the last PK sampling time point. The mean apparent plasma half-life of the drug was 20 h, which should be considered a preliminary estimate until results from studies with a longer duration of plasma sampling are available. A mean of 1.4-3.6% of the dose was recovered as unchanged drug in the urine over 48 h. Unconfirmed tumor regression ≥50% was observed in 2 patients, 1 with metastatic gastric carcinoma and 1 with esophageal cancer. Conclusions: The MTD of edotecarin administered IV over 2 h every 21 days was 15 mg/m2. The recommended dose for Phase II studies with a 3-week schedule (with 1 week permitted for recovery from toxicities, if needed) is 13 mg/m2. The observed safety profile and preliminary evidence of antitumor activity warrant further investigation of this drug in solid tumors.

KW - Dose-limiting toxicity

KW - Edotecarin

KW - Maximum tolerated dose

KW - Pharmacokinetics

KW - Topoisomerase I inhibitor

UR - http://www.scopus.com/inward/record.url?scp=33646477959&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646477959&partnerID=8YFLogxK

U2 - 10.1007/s00280-005-0149-6

DO - 10.1007/s00280-005-0149-6

M3 - Article

VL - 58

SP - 173

EP - 182

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 2

ER -